Research Progress of Microemulsion-based Drug Delivery Systems
Lü Fengfeng, Liu Shaojie, Liu Jie, Li Ganzuo, Zheng Liqiang*
(Key Laboratory of Colloid and Interface Chemistry (Shandong University), Jinan 250100)
Abstract The systems of microemulsions are currently of interest to the pharmaceutical scientist
because of their considerable potential to act as drug delivery vehicles by incorporating a wide range of
drugs. The microemulsion-based drug delivery systems are often used to control or delay the release of the
entrapped drugs. This paper gives an overview of the formation, phase behaviour and characterization of
microemulsions. The factors that influence the release of the incorporated drugs and the importance of the
nonionic surfactants, such as Span and Tween are also discussed. Key words Microemulsion, Drug Delivery LS LO LCS LS LO LCS
Fig.1 A pseudo-ternary phase diagram[26] Q = 2 ⋅ A ⋅ C ⋅ (D ⋅t ⋅ π )
[2] M L Lynch, A O Boateng, A Hippe et al. J. Coll. Inter. Sci., 2003, 264(2): 404~413. [3] B J Boyd. International Journal of Pharmaceutics, 2003, 260(2): 239~247. [4] C M Chang, R Bodmeier. International Journal of Pharmaceutics, 1998, 160(1): 51~60. [5] P Vermette, L Meagher, E Gagnon et al. J. Control. Release, 2002, 80(1-3): 179~195. [6] C Francesca, S A Gaia. Chemistry and Physics of Lipids, 2001, 109(1): 47~55. [7] R F Turchiello, F C Vena, Ph Maillard et al. Journal of Photochemistry and Photobiology B: Biology, 2003, 70(1): 1~6. [8]
[9] D Attwood, L R Currie, P H Elworthy. J. Colloid Interface Sci., 1974, 46: 249~256. [10] H N Bhargava, A Narurkar, L M Lieb. Pharm. Tech., 1987, 11: 46~52. [11] Th F Vandamme. Progress in Retinal and Eye Research, 2002, 21(1): 15~34. [12] D Attwood. Microemulsions. In: Colloidal Drug Delivery Systems. Marcell Dekker, New York, 1994: 31~71. [13] D P Evitts, O Olejnik, D G Musson et al. EP: 0 480 690 A1, 1991. [14] T Kissel, Y X Li, F Unger. Advanced Drug Delivery Reviews, 2002, 54(1): 99~134. [15] T J Franz. J. Invest. Dermatol, 1975, 64: 190~195.
[16] U Schmalfuss, R Neubert, W Wohlrab. J. Control. Release, 1997, 46(3): 279~285. [17] M Trotta, S Morel, M R Gasco. Pharmazie, 1997, 52(1): 50~53. [18] M J Alvarez-Figueroa, J Blanco-Mendez. Int. J. Pharm., 2001, 215(1): 57~65. [19] L Boltri, S Morel, M Trotta et al. J. Pharm. Belg., 1994, 49(2): 315~320. [20] S Kantaria, G D Rees, M J Lawrence. J. Control. Release, 1999, 60(2-3): 355~365. [21] J Kemken, A Ziegler, B W Muller. J. Pharm. Pharmacol., 1991, 43(2): 679~684. [22] J Kemken, A Ziegler, B W Muller. Methods Find. Exp. Clin. Pharmacol., 1991, 13(2): 361~365. [23] J Kemken, A Ziegler, B W Muller. Pharm. Res., 1992, 9(3): 554~558. [24]
. J. Surf. Sci. Tech., 1989, 5 (1): 29~39.
[26] A Yaghmur, A Aserin, N Carti. Coll. Surf. A, 2002, 209(1): 71~81. [27] M Kreilgaard. Advaned Drug Delivery Reviews, 2002, 54(1): S77~S98. [28] K Kreilgaard, E J Pedersen, J W Jaroszewski. J. Control. Release, 2000, 69(3): 421~433. [29] V H L Lee. Crit. Rev. Ther. Drug Carrier Syst., 1988, 5(1): 69~97. [30] S Benita, M Y Levy. J. Pharm. Sci., 1993, 82 (11): 1069. [31] K Kriwet, C C Muller-Goymann . Int. J. Pharm., 1995, 125(2): 231~242. [32] I Siebenbrodt, S Keipert. Eur. J. Pharm. Biopharm., 1993, 39 (1): 25~30. [33] J M Sarciaux, L Acar, P A Sado. Int. J. Pharm., 1995, 120(2): 127~136. [34] P P Constantinides. Pharm. Res., 1995, 12(1): 156~172. [35] E C Swenson, W J Curatolo. Adv. Drug Deliv. Rev., 1992, 8(1): 39~92. [36] B Baroli, M A Lopez-Quintela, M B Delgado-Charro et al. J. Control. Release, 2000, 69(1): 209~218. [37] K Jarvinen, T Jarvinen, A Urtti. Adv. Drug Deliv. Rev., 1995, 16(1): 3~19. [38] A Habe, S Keipert. Eur. J. Pharm. Biopharm., 1997, 43(1): 179~183. [39] S Keipert, G Schulz. Pharmazie, 1994, 49(1): 195~197. [40] I Siebenbrodt, S Keipert. Pharmazie, 1991, 46(2): 435~438. [41] I Siebenbrodt, S Keipert. Pharm. Ztg. Wiss., 1992,137(1): 135~141. [42] F S Barbault, R Gref, P Russo et al. J. Control. Release, 2002, 83(3): 365~375. [43]
[44] E Peira, P Scolari, M R Gasco. Int. J. Pharm., 2001, 226(1): 226, 47~51. [45] E Acosta, D H Kurlat, M Bisceglia et al. Coll. Surf. A, 1996,106(1): 11~21. [46] K Avgoustakis, A Beletsi, Z Panagi. J. Control. Release, 2002, 79(1): 123~135. [47] L A Dailey, T Schemhl, T Gessler. J. Control. Release, 2003, 86(1): 131~144. [48]
[50] W I Higuchi. J. Pharm. Sci., 1962, 51(3): 802~804. [51] G L Flynn, S H Yalkowsky, T J Roseman. J. Pharm. Sci., 1974, 63(2): 479~509.
LIFE ENHANCING CHIROPRACTIC CARE CENTER 8902 Seminole Trail Ruckersville, VA 22968Phone: (540) 308-1702 Fax: (888) 245-7701 NUTRITION EVALUATION: 09/15/2011 PATIENT INFORMATION DATA USED FOR ANALYSIS Height: 5'6"Weight: 145Blood Pressure: 139 / 95O2 Level: 83%Heart Rate: 98 PRIMARY SYMPTOMS 1. Hypercholesterolemia (High Cholesterol)2. High blood pressure3. Tachycardia (High Hea
Expand the scope of your practice by becoming the local chiropractic TMJ expert ffering temporomandibular joint (TMJ) services can ex- When the jaw functions properly, the right and left jaw joints pand your patient base and increase awareness of chiro- move as one unit. If this coordination of movement is upset, the jaw O practic treatment. Working with TMJ pati